What is Kolon TissueGene?
Kolon TissueGene, Inc. is a pioneering cell and gene therapy company focused on developing innovative treatments for degenerative conditions. Its lead product, TG-C, is an allogeneic cell and gene therapy designed to address osteoarthritis (OA) of the knee. The company is advancing its pipeline with plans for two pivotal Phase III clinical trials in the U.S., one of which is proceeding under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). This strategic positioning highlights Kolon TissueGene's commitment to rigorous clinical validation and market entry for its therapeutic candidates.
How much funding has Kolon TissueGene raised?
Kolon TissueGene has raised a total of $29.6M across 1 funding round:
Other Financing Round
$29.6M
Other Financing Round (2022): $29.6M with participation from Kolon Group
Key Investors in Kolon TissueGene
Kolon Group
Kolon Group is a South Korean conglomerate with diverse business interests, including chemicals, materials, and pharmaceuticals. Their investment in Kolon TissueGene likely reflects a strategic alignment with the group's focus on advanced healthcare and biotechnology.
What's next for Kolon TissueGene?
The substantial enterprise-level funding and recent strategic investment signal a critical growth phase for Kolon TissueGene. This capital infusion is expected to accelerate the company's ongoing Phase III clinical trials for TG-C, a key step towards potential regulatory approval and commercialization. The company's focus on a SPA agreement with the FDA indicates a clear pathway for clinical development and regulatory engagement. Future developments will likely center on trial progression, data analysis, and strategic partnerships to support the global launch of its first-in-class cell and gene therapy.
See full Kolon TissueGene company page
